Abstract
Species differences in the in vitro stability of sirolimus was assessed in plasma and whole blood in relation to red blood cell distribution. Fresh blood and plasma samples obtained from humans, rabbits, and rats were aliquoted and spiked with sirolimus. After incubation from 0 to 144 hr in a shaking water bath maintained at 37°C, sirolimus concentrations were quantified by a specific high-liquid performance chromatographic method. Sirolimus was unstable in both plasma and whole blood. Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats. Sirolimus stability is greater in whole blood compared with plasma in proportion to the whole blood/plasma ratio and hematocrit. In vivo instability may account for up to 36% of sirolimus clearance in humans and 13% in rabbits, and this is an important factor in the pharmacokinetics of this drug.
Footnotes
-
Send reprint requests to: William J. Jusko, Ph.D., Department of Pharmaceutics, State University of New York at Buffalo, 565 Hochstetter Hall, Buffalo, NY 14260.
-
Received June 25, 1997; accepted September 15, 1997
-
This work was supported by Grant GM 24211 from the National Institutes of Health and Fellowship support from Wyeth-Ayerst Research, Radnor, PA (G.M.F.).
- Abbreviations used are::
- RBC
- red blood cells
- FKBP
- FK-binding proteins
- WB
- whole blood
- PL
- plasma
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
